An Updated Outline of Klebsiella pneumoniae Resistance: Mechanisms and Treatments | ||||
| Egyptian Journal of Medical Microbiology | ||||
| Article 20, Volume 31, Issue 2, April 2022, Page 127-136 PDF (715.81 K) | ||||
| Document Type: Review articles | ||||
| DOI: 10.21608/ejmm.2022.229672 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Antony Sameh Soliman1; Michael Nazmy Agban  2
| ||||
| 1Pharmacy and Pharmaceutical Sciences, Ahram Canadian University (ACU), 6th October, Egypt. | ||||
| 2Microbiology and Immunology, Faculty of medicine, Assiut university, Egypt. | ||||
| Abstract | ||||
| Klebsiella pneumoniae (K. pneumoniae) is the most prominent type of Klebsiella spp. K. pneumoniae has become a worldwide health threat nowadays due to the emergence of hypervirulence and the extended-spectrum β-lactamases (ESBLs) producing strains that lead to the etiologies of hospital-acquired infections (HAI) and community-acquired infections (CAI). To survive within the host, the bacterium acquires virulence traits and techniques to resist antibiotics and the immune system response, hence it gradually becomes multidrug-resistant (MDR). Consequently, more antibiotics are rendered ineffective and thus inappropriate, causing more deteriorating clinical conditions, leading to a high mortality rate. While the vaccine of K. pneumoniae is still in progress, and since we are long past the beginning of antibiotic use, new concepts came to play to fight the bacterial infection such as the use of bacteriophage to destroy the prokaryotic cell and enhancement of the immune system. This article covers the most common genetic and structural mechanisms of resistance by which K. pneumoniae exhibits its resilience against the defense system and various antibiotics. It also reviews the epidemiology, the leading sites of infections, and possible treatment options for future use. | ||||
| Keywords | ||||
| K. pneumoniae; Resistance mechanisms; phage therapy | ||||
|
Statistics Article View: 297 PDF Download: 262 |
||||
